摘要
目的：探讨克拉霉素联合噻托溴胺治疗慢性阻塞性肺病（COPD）患者的疗效和肺功能变化．方法：将78例COPD患者随机平均分为观察组和对照组，观察组采用克拉霉素和噻托溴胺联合治疗，对照组采用噻托溴胺治疗，比较两组患者在治疗前后肺功能FEV1／FVC、肺炎衣原体Cpn-IgA、Cpn-IgG、Cpn-IgM阳性率和C反应蛋白（CRP）含量．结果：两组患者治疗后的肺功能均有显著改善，FEV1／FVC显著增加，且治疗后观察组的FEV1／FVC显著高于对照组（P＜0．05）；对照组的Cpn-IgA、Cpn-IgG、Cpn-IgM阳性率治疗前后差异无统计学意义（P＞0．05），观察组仅Cpn-IgM阳性率治疗后显著下降（P＜0．05）；两组患者治疗后的 CRP 含量均显著下降（P ＜0．05），且治疗后观察组的CRP含量比对照组下降更为显著（P＜0．05）．结论：克拉霉素联合噻托溴胺治疗COPD，具有明显的协同作用，值得更广泛的临床应用．
AIM：To explore the clinical efficacy and the changes of pulmonary function of clarithromycin combined with tiotropium bromide for treating chronic obstructive pulmonary disease （COPD）.METHODS：78 COPD patients were randomly divided into two groups averagely：the observation group and control group.The observation group was treated with clarithromycin and tiotropium bromide,the control group was treated with tiotropium bromide.The pulmonary function FEV1/FVC,Cpn-IgA,Cpn-IgG,Cpn-lgM and CRP were compared in the two groups before and after treatment.RESULTS：After treatment,the pulmonary ventilation function in the two groups improved significantly,and the observation group was more obvious than that in the control group （P〈0.05 ）.The positive rates of Cpn-IgA,Cpn-IgG and Cpn-IgM before and after treatment had no significant changes in the control group （P〉0.05 ）.The positive rate of Cpn-IgM de-creased significantly in the observation group （P〈0.05 ）.The CRP levels in the two groups decreased,and the observation group decreased more significantly than the control group （P〈0.05）.CONCLUSION：Clarithromycin combined with tiotropium bromide for treating COPD can enhance the synergic role of two drugs with better efficacy.It is worth widely applying in clinic.
出处
《转化医学电子杂志》
2014年第6期90-91,93,共3页
E-Journal of Translational Medicine
关键词
慢性阻塞性肺病
噻托溴胺
克拉霉素
chronic obstructive pulmonary disease
clarithromycin
tiotropium bromide
